Fernando M. Monteiro

Porto Alegre, RS, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 75 publications

Inguinal/pelvic lymph node involvement in penile squamous cell carcinoma by 18F-fluorodeoxyglucose PET/CT.

Inguinal/pelvic lymph node involvement in penile squamous cell carcinoma by 18F-fluorodeoxyglucose PET/CT.

Journal: BJU international

Published: August 19, 2026

Myositis in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-017 systematic review and meta-analysis.

Myositis in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-017 systematic review and meta-analysis.

Journal: Expert opinion on drug safety

Published: August 13, 2026

Structural Inequities in Global Oncology: Latin America and Caribbean Representation at the ASCO Genitourinary Cancers Symposium (2021-2025).

Structural Inequities in Global Oncology: Latin America and Caribbean Representation at the ASCO Genitourinary Cancers Symposium (2021-2025).

Journal: JCO global oncology

Published: July 22, 2026

Prostate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World Study.

Prostate Cancer Treatment Patterns and Inequities Among Racial Groups in Brazil's Public Health System: Insights From a 16-Year Real-World Study.

Journal: JCO global oncology

Published: May 29, 2026

Optimizing the Systemic Treatment for Metastatic Castration-Resistant Prostate Cancer in Lower-Middle-Income Countries: A 7-Year Analysis of the Brazilian Public Health System.

Optimizing the Systemic Treatment for Metastatic Castration-Resistant Prostate Cancer in Lower-Middle-Income Countries: A 7-Year Analysis of the Brazilian Public Health System.

Journal: JCO global oncology

Published: March 31, 2026

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).

Journal: Targeted oncology

Published: February 20, 2026

Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group.

Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group.

Journal: Expert opinion on pharmacotherapy

Published: February 04, 2026

An agent-based learning model integrating sex differences in renal cell carcinoma.

An agent-based learning model integrating sex differences in renal cell carcinoma.

Journal: Frontiers in immunology

Published: January 02, 2026

Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2EV project.

Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2EV project.

Journal: Clinical and experimental medicine

Published: November 25, 2025

Reply to: Comments on "Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)".

Reply to: Comments on "Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)".

Journal: International journal of cancer

Published: November 15, 2025

Immunotherapy in biliary tract cancer: effective but not enough?

Immunotherapy in biliary tract cancer: effective but not enough?

Journal: Expert review of clinical pharmacology

Published: November 13, 2025

Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study.

Journal: JCO global oncology

Published: October 29, 2025

Showing 1-12 of 75

Last Updated: 09/26/2026